PsyPost on MSN1mon
How SSRIs affect serotonin receptors: New findings from a depression study
However, 5-HT4 receptor binding activity decreased by 9% during the eight weeks of treatment in the neostriatum. There were ...
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent ...
Nasdaq5d
Silo Pharma Doses First Participant In IND-Enabling GLP Study Of SPC-15 For PTSD Treatment
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at addressing stress-induced psychiatric disorders like PTSD and anxiety. This study, which includes both toxicology and ...
Silo Pharma, Inc.: Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a development ...
Investing5d
Silo Pharma begins key study for PTSD treatment
SPC-15, an intranasal serotonin 5-HT4 receptor agonist, is designed to prevent post-traumatic stress disorder (PTSD). The company’s CEO, Eric Weisblum, stated that the study’s successful ...
Nasdaq1mon
Silo Pharma, Inc. Receives Issuance Notification for Patent Related to SPC-15 Treatment for PTSD
SPC-15 is a 5-HT4 receptor agonist with potential for expedited FDA approval, highlighting Silo's commitment to addressing serious psychiatric disorders and expanding its innovative drug ...
C&EN2y
Beyond Organic Solvents: Synthesis of a 5-HT4 Receptor Agonist in Water
Organic solvents are integral to the way we do chemistry today, but they are also hazardous, and many are derived from non-renewable petroleum. Adapting reactions, workups, and isolations to aqueous ...